In IBD, myokines such as irisin may balance and counteract the effects of proinflammatory adipokines released by a pathologically modified mWAT, thus contributing to the cross-talk between the skeletal muscle and adipose tissue [5,6,67]. This evidence concerns the gene FNDC5 and inflammatory bowel disease.